According to our new research study on “Joint Pain Injection Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Drug, Joint Type, and Distribution Channel,” the market is expected to reach US$ US$ 6,996.88 million by 2028 from US$ 3,667.45 million in 2020; it is estimated to grow at a CAGR of 8.5% from 2021 to 2028. The report highlights trends prevailing in the joint pain injection market and factors driving its growth. The growth of the joint pain injection market is mainly attributed to the factors such as the high prevalence of musculoskeletal disorders and increasing number of sports injuries. However, the high costs of joint repair therapies hinder the market growth.
Market Size Value in
(US$ 3,667.45 million in 2020)
Market Size Value by
(US$ 6,996.88 million by 2028)
(CAGR of 8.5% during 2021–2028)
No. of Pages
(By Drug; Joint Type and Distribution Channel)
(North America; Europe; Asia Pacific; Latin America; MEA)
(US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina)
(Revenue forecast, company ranking, competitive landscape, growth factors, and trends)
Get Sample PDF Copy of Joint Pain Injection Market at: https://www.theinsightpartners.com/sample/TIPRE00003536/
Joint pain injections provide faster relief from severe pain and reduce inflammation of joints. Several types of injections available in the market include corticosteroids injections, hyaluronic acid (HA) injections, platelet-rich plasma (PRP) injections, and placental tissue matrix (PTM) injections. The growth of the joint pain injection market is attributed to the factors such as high prevalence of musculoskeletal disorders and increasing number of sports injuries. However, high costs of joint repair therapies hinder the market growth.
High Prevalence of Musculoskeletal Disorders
Musculoskeletal disorders are medical conditions affecting muscles, bones, and joints of neck, shoulders, wrists, back, hips, legs, knees, and feet. These diseases include tendinitis, carpal tunnel syndrome, osteoarthritis, rheumatoid arthritis (RA), fibromyalgia, and bone fractures. As per the World Health Organization (WHO) factsheet updated in 2018, musculoskeletal conditions are the second-largest contributor to disability worldwide. According to the same, the prevalence and impact of musculoskeletal disorders is expected to rise with the increase in aging population and rise in the prevalence of risk factors of noncommunicable diseases (NCDs) worldwide. As per 2016 American Academy of Orthopedic Surgeons’ annual meeting data, ~1 in 2 adults is suffering from a musculoskeletal disorder in the US. Further, according to the Centers for Disease Control and Prevention (CDC), arthritis causes severe pain that affects millions of people in the US every year. Around one in four arthritis patients, i.e., ~15 million of total ~54 million patients, experiences severe arthritis-related joint pain.
Further, osteoarthritis (OA) is one of the most common joint disorders in the US, caused by the breakdown of joint cartilage between bones. It is also known as degenerative joint disease or “wear and tear” arthritis. As per the Centers for Disease Control and Prevention (CDC), more than 32.5 million adults in the US suffer from osteoarthritis. Similarly, as per the National Health Service (NHS), more than 10 million people in the UK have arthritis or other similar conditions that affect joints. As per the Bupa Health Insurance, osteoarthritis is the most common form of arthritis prevalent in the UK, it affects around the one-third of people aged 45 or more in the country, i.e., ~8.75 million people. Therefore, such high prevalence of musculoskeletal disorders in different countries is increasing the number of treatment procedures being carried out for the same, thereby driving the joint pain injection market growth.
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns.
Download the Latest COVID-19 Analysis on Joint Pain Injection Market Growth Research Report at: https://www.theinsightpartners.com/covid-analysis-sample/TIPRE00003536
The joint pain injection market, by drug, is segmented into hyaluronic acid, corticosteroid, and others. The corticosteroid segment held the largest share of the market in 2020, and it is further anticipated to register the highest CAGR during the forecast period.
Based on joint type, the joint pain injection market is segmented into knee, foot and ankle, shoulder and elbow, hips, and other applications. The knee segment held the largest market share in 2020 and is anticipated to register the highest CAGR in the market during the forecast period.
Joint Pain Injection Market: Competitive Landscape and Key Developments
Chugai Pharmaceutical Co., Ltd., Teva Pharmaceuticals, Bioventus Inc., Fidia Pharma USA Inc., Flexion Therapeutics, Inc., SEIKAGAKU CORPORATION, Ferring B.V., Sanofi, Anika Therapeutics, Inc., and OrthogenRx are among the leading companies operating in the joint pain injection market.
Order a Copy of Joint Pain Injection Market Shares, Strategies and Forecasts 2021-2028 Research Report at: https://www.theinsightpartners.com/buy/TIPRE00003536/
Browse Related Reports and get Sample copy
Joint Repair Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Knee Reconstruction Devices, Total Knee Replacement, Partial Knee Replacement, Revision Total Knee Replacement, Hip Reconstruction Devices, Others); Indication (Osteoarthritis, Rheumatoid Arthritis, Hip Dysplasia, Orthopaedic Trauma, Others); Joint Type (Knee, Hip, Shoulder, Ankle, Others); End User (Hospitals, Rehabilitation Centers, Others); and Geography
Pain Patch Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Type (Opioid, Non-Opioid); Mode of administration (Metered Dose, Microneedle Patches); Therapeutic Use (Pain relief, Anaesthesia, Cough Suppression, Smoking Cessation)
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Company Name: The Insight Partners
Contact Person: Sameer Joshi
Email: Send Email